There have been numerous dendritic vaccine efforts that failed, which is the key reason the shorts have been so successful here. People tried with Dendritic ace vaccines before and failed.
Additionally, one would probably do well to investigate further the difference in their version. Seems they have different language suggesting it is not the “same” even with the term “Lysate”. They say “Tumor Lysate, Particle Only (TLPO) vaccine”. The particle only concept should be explored a bit more. There have been other wannabes that have disappeared over time, but of course there will be efforts also for alternatives if NWBO pairs up with a single Big Pharma, just like there are numerous Car-T and Checkpoint Inhibitor trials and drugs with different companies.
Not really a reason for anyone to freak out given NWBO has orphan status, a successfully completed Phase 3, and other significant accomplishments under its belt including technology to automate production.
It is also an important reason for them to keep automation technology closely held rather than giving everyone that asks for it, their own machine.
As for patents, patents are not for “dendritic cells”, you can’t patent a natural human cell. You patent the processes that allow you to derive your drug using that cell. NWBO has numerous patents and continues to evolve its process with Flaskworks, and patents for new processes have been issued and are in process. Plus they are farther ahead on other research like combinations.
I would not worry about competitors. Many will try, and they are still far behind, relatively speaking. There will be room for competitors, if any survive.
News 
Market Data 
Discover 
